{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:28:35Z","timestamp":1791584915373,"version":"4.3.4"},"reference-count":15,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031365","name":"Oslo universitetssykehus HF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031365","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.trecan.2025.05.007","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T12:32:33Z","timestamp":1750077153000},"page":"722-725","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["STEAP1: a promising target in prostate cancer therapy"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3923-144X","authenticated-orcid":false,"given":"Rohit","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon Amund","family":"Kyte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2025.05.007_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.trecan.2025.05.007_bb0010","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.trecan.2025.05.007_bb0015","article-title":"Regulatory roles of six-transmembrane epithelial antigen of the prostate family members in the occurrence and development of malignant tumors","volume":"9","author":"Chen","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.trecan.2025.05.007_bb0020","doi-asserted-by":"crossref","first-page":"9502","DOI":"10.1074\/jbc.RA120.013690","article-title":"Cryo-electron microscopy structure and potential enzymatic function of human six-transmembrane epithelial antigen of the prostate 1 (STEAP1)","volume":"295","author":"Oosterheert","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.trecan.2025.05.007_bb0025","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.bbrc.2012.10.123","article-title":"STEAP1 is overexpressed in cancers: a promising therapeutic target","volume":"429","author":"Moreaux","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.trecan.2025.05.007_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2013.08.028","article-title":"STEAP1 is overexpressed in prostate cancer and prostatic intraepithelial neoplasia lesions, and it is positively associated with Gleason score","volume":"32","author":"Gomes","year":"2014","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.trecan.2025.05.007_bb0035","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/s41467-023-37874-2","article-title":"Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy","volume":"14","author":"Bhatia","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2025.05.007_bb0040","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/2159-8290.CD-23-0984","article-title":"AMG 509 (xaluritamig), an anti-STEAP1 XmAb 2+1 T-cell redirecting immune therapy with avidity-dependent activity against prostate cancer","volume":"14","author":"Nolan-Stevaux","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2025.05.007_bb0045","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1158\/2159-8290.CD-23-0964","article-title":"Xaluritamig, a STEAP1 \u00d7 CD3 XmAb 2+1 immune therapy for metastatic castration-resistant prostate cancer: results from dose exploration in a first-in-human study","volume":"14","author":"Kelly","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2025.05.007_bb0050","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1158\/1541-7786.MCR-24-0903","article-title":"Exploring STEAP1 expression in prostate cancer cells in response to androgen deprivation and in small extracellular vesicles","volume":"23","author":"Bizzaro","year":"2025","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.trecan.2025.05.007_bb0055","doi-asserted-by":"crossref","first-page":"S1000","DOI":"10.1016\/j.annonc.2024.08.1741","article-title":"1660TiP First-in-human study of ABBV-969, a dual variable antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"35","author":"Berger","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2025.05.007_bb0060","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1200\/JCO.19.00646","article-title":"Phase I study of DSTP3086S, an antibody-drug conjugate targeting six-transmembrane epithelial antigen of prostate 1, in metastatic castration-resistant prostate cancer","volume":"37","author":"Danila","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.05.007_bb0065","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS5119","article-title":"Prime-boost immunotherapeutic trial in men with biochemical recurrence after definitive local therapy for prostate cancer","volume":"41","author":"Stein","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2025.05.007_bb0070","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.omto.2022.06.007","article-title":"Development of STEAP1 targeting chimeric antigen receptor for adoptive cell therapy against cancer","volume":"26","author":"Jin","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.trecan.2025.05.007_bb0075","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.2967\/jnumed.118.222844","article-title":"Imaging patients with metastatic castration-resistant prostate cancer using (89)Zr-DFO-MSTP2109A anti-STEAP1 antibody","volume":"60","author":"Carrasquillo","year":"2019","journal-title":"J. Nucl. Med."}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803325001414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803325001414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T15:23:19Z","timestamp":1755012199000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405803325001414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2405803325001414"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2025.05.007","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"STEAP1: a promising target in prostate cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Trends in Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trecan.2025.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}